Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Cellenkos has filed a proposal with the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase I / II clinical trial of CK0802 to treat Covid-19 mediated acute respiratory distress syndrome (CoV-ARDS).
The company plans to use its expertise with CK0802 for other inflammatory diseases, such as amyotrophic lateral sclerosis. The aim is to expedite the drug candidate’s development to treat respiratory complications caused by the novel coronavirus infection.
Cellenkos has a manufacturing facility in Houston, Texas, US to produce clinical cell therapy products. The company received two FDA-INDs in inflammatory bone marrow failure and